1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Infinity cuts 20% of workforce as it refocuses on PI3K and retaspimycin

 
• By Mandy Jackson

Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.

Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.

Infinity had $104.6 million in cash and investments as of 30 June compared to a $104.9 million cash balance on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.